What the Cochrane Evidence Says About Certolizumab Pegol for Crohn's Disease

When Crohn's disease does not respond to standard anti-inflammatory medications and immunosuppressants, biologic therapies become the next step. Several anti-TNF biologics are now available for Crohn's disease, but one of them, certolizumab pegol (Cimzia), has a structural characteristic that sets it apart from all the others and that matters for some specific groups of patients.

A 2022 Cochrane systematic review pooled the best available randomised trial data on certolizumab pegol to determine how effective it is for keeping Crohn's disease in remission after an initial response to treatment. This article explains what the review found, what makes certolizumab different from other biologics in the same class, and what the results mean for patients living with Crohn's disease.

What Crohn's Disease Is

Crohn's disease is a chronic inflammatory bowel condition that can affect any part of the digestive tract, from the mouth to the anus. The NHS describes it as a lifelong condition characterised by inflammation of the lining of the digestive system. Symptoms include diarrhoea, abdominal cramps, blood in the stool, fatigue, and unintended weight loss. Like other forms of inflammatory bowel disease (IBD), Crohn's tends to follow a relapsing and remitting course: periods when symptoms are active (flares) alternate with periods when they ease or disappear (remission).

Treatment typically begins with anti-inflammatory drugs such as corticosteroids, progresses to immunomodulators such as azathioprine or methotrexate, and moves to biologic therapies when those approaches are insufficient. It is in this later stage of the treatment pathway that certolizumab pegol is most commonly used.

What Certolizumab Pegol Is

Certolizumab pegol is a biologic medicine that targets tumour necrosis factor alpha (TNF-alpha), a signalling protein that plays a central role in driving the immune overactivity that causes inflammation in Crohn's disease. It belongs to the anti-TNF class of biologics, which also includes infliximab, adalimumab, and golimumab, but its molecular structure is meaningfully different from all three.

Unlike other anti-TNF drugs, certolizumab is a PEGylated Fab' fragment rather than a whole monoclonal antibody. This means it is missing the Fc region that the other anti-TNF biologics carry. The Cochrane review background (pubmed:35771590) explains the significance of this structural difference. The Fc region in standard antibodies is responsible for several downstream effects, including activation of the complement system and interaction with Fc receptors on immune cells. Certolizumab, lacking this region, does not trigger these pathways.

The clinical consequence that matters most for certain patients is in pregnancy. The Fc region is also the mechanism by which antibodies are actively transported across the placenta to the developing foetus. Because certolizumab has no Fc region, this active transport mechanism does not apply to it, and the drug crosses the placenta at substantially lower levels than infliximab, adalimumab, or other intact antibody biologics. For this reason, certolizumab is widely regarded as the anti-TNF biologic of choice when a woman with active Crohn's disease requires biological therapy during pregnancy. Very low concentrations have also been detected in breast milk compared with other anti-TNF agents.

Certolizumab is administered as a subcutaneous injection rather than an intravenous infusion. The standard dosing schedule for Crohn's disease is 400 mg injected at weeks 0, 2, and 4 to induce a response, followed by 400 mg every four weeks for long-term maintenance.

What the Cochrane Review Did

The 2022 Cochrane systematic review (pubmed:35771590) was conducted by Okabayashi and colleagues and published in the Cochrane Database of Systematic Reviews. It focused specifically on whether certolizumab pegol can maintain remission in adults with Crohn's disease who achieved a clinical response during induction therapy.

Cochrane reviews use a structured, pre-specified methodology: a comprehensive search of trial databases to identify all relevant randomised controlled trials, independent and standardised assessment of each study's risk of bias, and statistical pooling of results across trials (meta-analysis). The Cochrane Database of Systematic Reviews is a Tier 1 source of evidence synthesis in clinical medicine.

The primary evidence base for the review's maintenance analysis was the PRECISE 2 randomised controlled trial. In PRECISE 2, adults with moderately to severely active Crohn's disease received certolizumab 400 mg at weeks 0, 2, and 4 during the induction phase. Those who had achieved a clinical response (defined as a reduction of at least 100 points in the Crohn's Disease Activity Index, or CDAI) at week 6 were then randomised to either continue certolizumab 400 mg every four weeks or switch to placebo through week 26. The trial enrolled both patients who were naive to biologic therapy and patients who had previously used a TNF inhibitor, though prior TNF inhibitor use was an exclusion criterion in PRECISE 2's primary analysis.

What the Results Showed: Maintaining Clinical Response

The Cochrane review found that certolizumab pegol was significantly more effective than placebo for maintaining clinical response in Crohn's disease at week 26.

In the PRECISE 2 maintenance data, approximately 48 to 49 percent of participants who continued certolizumab maintained a clinical response at week 26, compared with approximately 29 percent of those switched to placebo. This translates to a risk ratio significantly in favour of certolizumab: on an absolute basis, roughly one additional patient in five maintained a response with certolizumab compared with placebo. The review characterised this maintenance benefit as clinically meaningful and statistically robust.

What the Results Showed: Clinical Remission

For remission specifically (defined as a CDAI score below 150, indicating low symptomatic burden), the Cochrane review also found certolizumab significantly superior to placebo at week 26.

The PRECISE 2 data showed approximately 29 percent of certolizumab-treated participants achieving clinical remission at week 26, compared with approximately 16 percent of those on placebo. This represents a statistically significant and clinically relevant difference. The reviewers noted that the CDAI-based remission definition used in the PRECISE trials reflects patient-reported symptom burden rather than direct visualisation of the bowel, and that endoscopic and histological outcomes were not primary endpoints in the assessed trials. This is a limitation of the evidence base, as contemporary gastroenterology guidelines increasingly emphasise endoscopic healing as a treatment target alongside symptom control.

Safety: What the Review Found

The Cochrane review found no significant difference between certolizumab and placebo in the overall rates of adverse events, serious adverse events, or withdrawals due to adverse effects during the maintenance period.

Infection rates, which are a primary safety concern with biologic immunosuppressant therapy, were not significantly higher with certolizumab than with placebo in the pooled maintenance data. The reviewers acknowledged that the evidence base for safety came mainly from the PRECISE 2 trial and that post-marketing surveillance and long-term real-world registries provide important additional safety information that was outside the scope of this review.

One finding the review noted, consistent with the anti-TNF class overall, is the phenomenon of anti-drug antibody formation. Patients who develop antibodies to certolizumab during treatment tend to have lower clinical response rates. In clinical practice, co-administration of an immunomodulator (such as azathioprine) may reduce antibody formation and preserve the drug's effectiveness over time. Patients should discuss this with their IBD team when certolizumab is being considered or is already being used.

Where Certolizumab Stands Today

In the United Kingdom, NICE guidance (TA387) recommends certolizumab pegol as an option for treating moderately to severely active Crohn's disease in adults whose disease has not responded adequately to or who cannot tolerate conventional therapy. This positions certolizumab within the broader anti-TNF biologic category for Crohn's disease management.

Certolizumab is also approved by the US FDA and the European Medicines Agency (EMA) for moderately to severely active Crohn's disease in adults. Its subcutaneous route of administration and monthly maintenance dosing (after the initial three loading doses) offer a practical alternative to intravenously administered biologics for patients who prefer home injection to clinic visits.

The drug's distinctive pregnancy safety profile has made it a topic of specific interest in gastroenterology and obstetrics. International consensus guidelines on IBD in pregnancy, including those from ECCO (the European Crohn's and Colitis Organisation), note certolizumab as the preferred anti-TNF option during conception and pregnancy when biologic therapy is necessary to maintain disease control.

What This Evidence Means for Patients

The Cochrane review provides patients with Crohn's disease with a high-quality, independent summary of the evidence on certolizumab pegol for maintenance of remission. The overall picture is clear: certolizumab significantly outperforms placebo for keeping Crohn's disease under control in patients who responded to induction therapy, with a response advantage of around 20 percentage points and a remission advantage of around 13 percentage points at six months.

The safety data reviewed does not reveal a significant increase in adverse events compared with placebo, though patients should remain in discussion with their IBD team about the full risk picture, including longer-term data and individual risk factors.

What makes certolizumab distinctive within the anti-TNF class is not primarily its clinical efficacy, which is broadly comparable to other anti-TNF biologics, but its structural characteristics. For patients with Crohn's disease who are pregnant, planning to become pregnant, or breastfeeding, the substantially lower placental transfer compared with other anti-TNF agents is a genuinely relevant consideration that may make certolizumab the preferred choice in those circumstances. Patients should raise this with their gastroenterologist or IBD team if it applies to their situation.